Antineoplastic Agents
"Antineoplastic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
Descriptor ID |
D000970
|
MeSH Number(s) |
D27.505.954.248
|
Concept/Terms |
Antineoplastic Agents- Antineoplastic Agents
- Agents, Antineoplastic
- Antitumor Drugs
- Drugs, Antitumor
- Antitumor Agents
- Agents, Antitumor
- Antineoplastic Drugs
- Drugs, Antineoplastic
- Antineoplastics
|
Below are MeSH descriptors whose meaning is more general than "Antineoplastic Agents".
Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Agents".
This graph shows the total number of publications written about "Antineoplastic Agents" by people in this website by year, and whether "Antineoplastic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
1980 | 6 | 6 | 12 | 1981 | 5 | 3 | 8 | 1982 | 9 | 4 | 13 | 1983 | 6 | 1 | 7 | 1984 | 3 | 0 | 3 | 1985 | 2 | 1 | 3 | 1986 | 4 | 2 | 6 | 1987 | 3 | 2 | 5 | 1988 | 6 | 0 | 6 | 1989 | 6 | 2 | 8 | 1990 | 2 | 3 | 5 | 1991 | 3 | 1 | 4 | 1992 | 6 | 5 | 11 | 1993 | 7 | 1 | 8 | 1994 | 12 | 2 | 14 | 1995 | 6 | 2 | 8 | 1996 | 13 | 3 | 16 | 1997 | 8 | 1 | 9 | 1998 | 24 | 7 | 31 | 1999 | 10 | 9 | 19 | 2000 | 19 | 9 | 28 | 2001 | 25 | 7 | 32 | 2002 | 41 | 14 | 55 | 2003 | 34 | 12 | 46 | 2004 | 43 | 14 | 57 | 2005 | 34 | 21 | 55 | 2006 | 42 | 20 | 62 | 2007 | 49 | 20 | 69 | 2008 | 38 | 19 | 57 | 2009 | 45 | 26 | 71 | 2010 | 61 | 29 | 90 | 2011 | 64 | 19 | 83 | 2012 | 58 | 27 | 85 | 2013 | 56 | 25 | 81 | 2014 | 73 | 24 | 97 | 2015 | 77 | 35 | 112 | 2016 | 65 | 31 | 96 | 2017 | 46 | 27 | 73 | 2018 | 41 | 26 | 67 | 2019 | 46 | 22 | 68 | 2020 | 14 | 12 | 26 | 2021 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Antineoplastic Agents" by people in Profiles.
-
Passaro A, Bestvina C, Velez Velez M, Garassino MC, Garon E, Peters S. Severity of COVID-19 in patients with lung cancer: evidence and challenges. J Immunother Cancer. 2021 03; 9(3).
-
Wu JT, Kwon DH, Glover MJ, Henry S, Wood D, Rubin DL, Koshkin VS, Schapira L, Shah SA. Changes in Cancer Management due to COVID-19 Illness in Patients with Cancer in Northern California. JCO Oncol Pract. 2021 Mar; 17(3):e377-e385.
-
Pillai A, Ahn J, Kulik L. Integrating Genomics Into Clinical Practice in Hepatocellular Carcinoma: The Challenges Ahead. Am J Gastroenterol. 2020 12; 115(12):1960-1969.
-
Arber DA, Erba HP. Diagnosis and Treatment of Patients With Acute Myeloid Leukemia With Myelodysplasia-Related Changes (AML-MRC). Am J Clin Pathol. 2020 11 04; 154(6):731-741.
-
Schuster B, Junkin M, Kashaf SS, Romero-Calvo I, Kirby K, Matthews J, Weber CR, Rzhetsky A, White KP, Tay S. Automated microfluidic platform for dynamic and combinatorial drug screening of tumor organoids. Nat Commun. 2020 10 19; 11(1):5271.
-
Rank CU, Lynggaard LS, Als-Nielsen B, Stock W, Toft N, Nielsen OJ, Frandsen TL, Tuckuviene R, Schmiegelow K. Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia. Cochrane Database Syst Rev. 2020 10 10; 10:CD013399.
-
Mittendorf EA, Zhang H, Barrios CH, Saji S, Jung KH, Hegg R, Koehler A, Sohn J, Iwata H, Telli ML, Ferrario C, Punie K, Penault-Llorca F, Patel S, Duc AN, Liste-Hermoso M, Maiya V, Molinero L, Chui SY, Harbeck N. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. Lancet. 2020 10 10; 396(10257):1090-1100.
-
Donington JS, Paulus R, Edelman MJ, Krasna MJ, Le QT, Suntharalingam M, Loo BW, Hu C, Bradley JD. Resection following concurrent chemotherapy and high-dose radiation for stage IIIA non-small cell lung cancer. J Thorac Cardiovasc Surg. 2020 11; 160(5):1331-1345.e1.
-
Paik PK, Felip E, Veillon R, Sakai H, Cortot AB, Garassino MC, Mazieres J, Viteri S, Senellart H, Van Meerbeeck J, Raskin J, Reinmuth N, Conte P, Kowalski D, Cho BC, Patel JD, Horn L, Griesinger F, Han JY, Kim YC, Chang GC, Tsai CL, Yang JC, Chen YM, Smit EF, van der Wekken AJ, Kato T, Juraeva D, Stroh C, Bruns R, Straub J, Johne A, Scheele J, Heymach JV, Le X. Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations. N Engl J Med. 2020 09 03; 383(10):931-943.
-
Abou-Alfa GK, Macarulla T, Javle MM, Kelley RK, Lubner SJ, Adeva J, Cleary JM, Catenacci DV, Borad MJ, Bridgewater J, Harris WP, Murphy AG, Oh DY, Whisenant J, Lowery MA, Goyal L, Shroff RT, El-Khoueiry AB, Fan B, Wu B, Chamberlain CX, Jiang L, Gliser C, Pandya SS, Valle JW, Zhu AX. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020 06; 21(6):796-807.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|